Technical Analysis for SYRS - Syros Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 6.75 0.75% 0.05
SYRS closed up 0.75 percent on Friday, January 18, 2019, on 80 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical SYRS trend table...

Date Alert Name Type % Chg
Jan 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 18 Narrow Range Bar Range Contraction 0.00%
Jan 18 NR7 Range Contraction 0.00%
Jan 18 Stochastic Reached Overbought Strength 0.00%
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Weak, Overbought and Reversal Signs Reversal 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 18 Up 3 Days in a Row Strength 0.00%
Jan 18 Up 4 Days in a Row Strength 0.00%
Jan 17 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.75%

Older signals for SYRS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing medicines that control genes to transform the lives of patients with cancer, immune-mediated diseases, and other diseases. The company's gene control platform identifies gene control targets linked to genomically defined patient populations and drugging gene control targets; identifies potential new drug targets across a range of diseases; provides lens for diagnosing and segmenting patients, including those with complex/multi-factorial diseases; and allows users to advance a wave of medicines with the potential to influence multiple drivers of disease through a single target. Its pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor for acute leukemia. Syros Pharmaceuticals, Inc. was formerly known as LS22, Inc. Syros Pharmaceuticals, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Is SYRS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.86
52 Week Low 5.39
Average Volume 142,361
200-Day Moving Average 10.2337
50-Day Moving Average 7.0651
20-Day Moving Average 6.2713
10-Day Moving Average 6.493
Average True Range 0.5557
ADX 12.57
+DI 17.212
-DI 13.5747
Chandelier Exit (Long, 3 ATRs ) 6.0129
Chandelier Exit (Short, 3 ATRs ) 7.0571
Upper Bollinger Band 6.9856
Lower Bollinger Band 5.557
Percent B (%b) 0.84
BandWidth 22.779966
MACD Line -0.1451
MACD Signal Line -0.2542
MACD Histogram 0.1091
Fundamentals Value
Market Cap 177.26 Million
Num Shares 26.3 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -3.20
Price-to-Sales 289.82
Price-to-Book 4.51
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.14
Resistance 3 (R3) 7.13 6.98 7.08
Resistance 2 (R2) 6.98 6.88 6.99 7.05
Resistance 1 (R1) 6.87 6.82 6.93 6.88 7.03
Pivot Point 6.72 6.72 6.75 6.73 6.72
Support 1 (S1) 6.61 6.62 6.67 6.62 6.47
Support 2 (S2) 6.46 6.56 6.47 6.45
Support 3 (S3) 6.35 6.46 6.43
Support 4 (S4) 6.36